{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:49:37Z","timestamp":1791503377836,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126204","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:01:58Z","timestamp":1791388918000},"page":"126204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone"],"prefix":"10.1016","volume":"491","author":[{"given":"Vincenzo","family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Maria","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Quartetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicasio","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2026.126204_bb0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","article-title":"Friedreich\u2019s ataxia-a rare multisystem disease","volume":"24","author":"Reetz","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126204_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia- pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.jns.2026.126204_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119809","article-title":"A multiple animal and cellular models approach to study frataxin deficiency in Friedreich ataxia","volume":"1871","author":"Mosbach","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"4","key":"10.1016\/j.jns.2026.126204_bb0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","article-title":"Molecular mechanisms and therapeutics for the GAA\u00b7TTC expansion disease Friedreich Ataxia","volume":"16","author":"Gottesfeld","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jns.2026.126204_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich\u2019s ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook","year":"2017","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jns.2026.126204_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinph.2026.2111933","article-title":"Neurophysiological assessment of disease severity in Friedreich\u2019s ataxia: a study of brainstem auditory and visual evoked potentials","author":"Maccora","year":"2026","journal-title":"Clin. Neurophysiol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2026.126204_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jnc.12317","article-title":"Clinical features of Friedreich\u2019s ataxia: classical and atypical phenotypes","volume":"126","author":"Parkinson","year":"2013","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.jns.2026.126204_bb0040","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.3390\/ijms23116297","article-title":"Neuroinflammation in Friedreich\u2019s Ataxia","volume":"23","author":"Apolloni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.jns.2026.126204_bb0045","doi-asserted-by":"crossref","first-page":"9747","DOI":"10.3390\/ijms26199747","article-title":"Synthesis and biological profile of omaveloxolone: the cornerstone for Friedreich Ataxia treatment","volume":"26","author":"Cordaro","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2026.126204_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2026.126204_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2026.126204_bb0060","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9960721","article-title":"NRF2 exerts anti-inflammatory effects in LPS-induced gEECs by inhibiting the activation of the NF-\u03baB","volume":"2021","author":"Bao","year":"2021","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.jns.2026.126204_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.intimp.2019.03.023","article-title":"Nrf2 exerts mixed inflammation and glucose metabolism regulatory effects on murine RAW264.7 macrophages","volume":"71","author":"Ding","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.jns.2026.126204_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134235","article-title":"NRF2 signaling negatively regulates phorbol-12-myristate-13-acetate (PMA)-induced differentiation of human monocytic U937 cells into pro-inflammatory macrophages","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jns.2026.126204_bb0075","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.jns.2026.126204_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.126204_bb0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13023-024-03474-6","article-title":"Safety and efficacy of omaveloxolone v\/s placebo for the treatment of Friedreich\u2019s ataxia in patients aged more than 16 years: a systematic review","volume":"19","author":"Umrao","year":"2024","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"10.1016\/j.jns.2026.126204_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich Ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126204_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich\u2019s Ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2026.126204_bb0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00415-025-13487-1","article-title":"Early experience on omaveloxolone in adult patients with Friedreich\u2019s Ataxia: a real-world observational study","volume":"272","author":"Lima","year":"2025","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126204_bb0105","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40120-025-00752-8","article-title":"Managing aminotransferase elevations in patients with Friedreich Ataxia treated with Omaveloxolone: A review and expert opinion on use considerations","volume":"14","author":"Perlman","year":"2025","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.jns.2026.126204_bb0110","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1212\/NXG.0000000000000380","article-title":"Rating scales for rare neurological diseases: what are we learning from Friedreich Ataxia?","volume":"5","author":"Pandolfo","year":"2019","journal-title":"Neurol. Genet."},{"issue":"2","key":"10.1016\/j.jns.2026.126204_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.28313","article-title":"Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations","volume":"36","author":"Perez-Lloret","year":"2021","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2026.126204_bb0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.126204_bb0125","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.jns.2026.126204_bb0130","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","article-title":"Natural history of friedreich ataxia: heterogeneity of neurologic progression and consequences for clinical trial design","volume":"99","author":"Rummey","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2026.126204_bb0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.27237","article-title":"Neuroimaging Biomarkers for Friedreich Ataxia: A Cross-Sectional Analysis of the TRACK-FA Study","volume":"98","author":"Georgiou-Karistianis","year":"2025","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.jns.2026.126204_bb0140","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-026-01312-w","article-title":"Impact of omaveloxolone on serum lipids in patients with Friedreich Ataxia: a 1-year real-world analysis","volume":"40","author":"Buchinger","year":"2026","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2026.126204_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2026.104128","article-title":"Sex-based differences in the NRF2 oxidative stress response: implications for precision therapeutics","volume":"92","author":"Russomanno","year":"2026","journal-title":"Redox Biol."},{"issue":"10","key":"10.1016\/j.jns.2026.126204_bb0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40263-024-01113-z","article-title":"New and emerging drug and gene therapies for Friedreich Ataxia","volume":"38","author":"Scott","year":"2024","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jns.2026.126204_bb0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mds.28825","article-title":"Neuroinflammation in the cerebellum and brainstem in Friedreich Ataxia: an [18F]-FEMPA PET study","volume":"37","author":"Khan","year":"2022","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2026.126204_bb0160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.29819","article-title":"Genetic determined iron starvation signature in Friedreich\u2019s Ataxia","volume":"39","author":"Grander","year":"2024","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2026.126204_bb0165","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000415","article-title":"Neurologic outcomes in Friedreich Ataxia: study of a single-site cohort","volume":"6","author":"Pandolfo","year":"2020","journal-title":"Neurol. Genet."},{"issue":"9","key":"10.1016\/j.jns.2026.126204_bb0170","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich Ataxia: quantitative characterization over 5 years","volume":"3","author":"Patel","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126204_bb0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1212\/NXG.0000000000000371","article-title":"Psychometric properties of the Friedreich Ataxia Rating Scale","volume":"5","author":"Rummey","year":"2019","journal-title":"Neurol. Genet."},{"issue":"1","key":"10.1016\/j.jns.2026.126204_bb0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich Ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.126204_bb0185","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","article-title":"Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study","volume":"20","author":"Reetz","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126204_bb0190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-025-01065-y","article-title":"A global perspective on research advances and future challenges in Friedreich Ataxia","volume":"21","author":"Indelicato","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126204_bb0195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/WCO.0000000000000817","article-title":"The biological basis of chronic fatigue: neuroinflammation and innate immunity","volume":"33","author":"Omdal","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2026.126204_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/758314","article-title":"Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?","volume":"2015","author":"Malekzadeh","year":"2015","journal-title":"Dis. Markers"},{"issue":"9","key":"10.1016\/j.jns.2026.126204_bb0205","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/biomedicines10092058","article-title":"Fatigue in multiple sclerosis is associated with reduced expression of interleukin-10 and worse prospective disease activity","volume":"10","author":"Gilio","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jns.2026.126204_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126204_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.37349\/ent.2023.00045","article-title":"Muscle fatigue and exercise-related biomarkers in amyotrophic lateral sclerosis","volume":"3","author":"Bianchi","year":"2023","journal-title":"Explor. Neuroprot. Ther."},{"issue":"8","key":"10.1016\/j.jns.2026.126204_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10259","article-title":"Practice effects in performance outcome measures in patients living with neurologic disorders - a systematic review","volume":"8","author":"Holm","year":"2022","journal-title":"Heliyon"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:05:37Z","timestamp":1791500737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"alternative-id":["S0022510X26004867"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126204","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126204"}}